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Thoracic aorta calciumThe inherent limitations of traditional risk factor-based cardio-
vascular disease (CVD) risk assessment [1] have triggered the
development and implementation of imaging tests aimed at
directly measuring the presence and burden of subclinical athero-
sclerosis in diverse vascular beds within individual patients. Such
individualized disease assessment clearly trumps risk factors as the
strongest predictor of incident CVD events and death [2]. The
promising results of incorporating such imaging-based risk infor-
mation into clinical decision-making has led experts to advance a
CVD risk assessment paradigm shift from a risk-factor based model
(prediction) to an atherosclerosis imaging-based approach (disease
detection).
Among available imaging modalities, coronary artery calcium
(CAC) using non-contrast computed tomography is considered one
of the most powerful tools for absolute CVD risk assessment in
asymptomatic adults [3]. Notwithstanding its essential limitation
for ruling out the presence of early non-calciﬁed plaque, CAC has a
very high sensitivity for the detection of clinically relevant coronary
atherosclerosis in asymptomatic adults [4], which results in a high
negative predictive value. Moreover, CAC appears particularly
valuable as a prognostic test. Beyond its well-known ability to
identify those individuals more likely to have CVD eventsDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.10.100.
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large clinical cohorts have shown asymptomatic subjects with zero
CAC (CAC ¼ 0) to have an excellent cardiovascular prognosis
regardless of their age, sex, ethnic group, and burden of traditional
risk factors [5]. Thus, CAC ¼ 0 stands as perhaps the most powerful
negative risk factor for near- and mid-term development of coro-
nary events in asymptomatic adults [6]. In a context of population
aging and cost-constrained healthcare systems, the accurate iden-
tiﬁcation of “who not to treat” has important public health impli-
cations and may lead to large cost savings [7].
Hence, the clinician will ﬁnd a CAC ¼ 0 particularly informative
in the context of CVD risk assessment of asymptomatic subjects
considered at “intermediate” risk by traditional risk scores (where
therapeutic decision-making is commonly uncertain). Nonetheless,
in order to build decision-making around CAC results that might
lead towithholding or reducing preventive pharmacotherapies, the
clinician requires reliable information regarding the stability of that
CAC ¼ 0 over time: i.e., the “warranty period” of that result, during
which it is safe to assume that the patient is likely to have persistent
CAC ¼ 0, remaining at low risk for CVD events and not in need for
further interventions or repeat CAC evaluation. Indeed aging, and
thus a longer exposure to risk factors, may lead to the development
of coronary atherosclerosis and calciﬁcations in individuals with
initial CAC¼ 0. Previous studies have reported low conversion rates
to CAC > 0 after 4e5 years of follow-up (z20%, including 1% con-
version rates to CAC > 100) [8] and very low CVD event rates [5,9] in
subjects with CAC ¼ 0. Nevertheless, uncertainty regarding when
and inwhich patients this conversion and subsequent risk shift will
occur has hampered incorporation of CAC ¼ 0 into clinical guide-
lines, leading to the continuation of costly treatments with po-
tential side-effects in those unlikely to have events, “just in case”.1. Deﬁning the warranty period of CAC¼ 0: a multidimaging
approach
The multi-imaging approach, rooted in the systemic nature of
atherosclerosis [10] and the heterogeneity by which it affects
different vascular beds, integrates the information provided by
complementary, non-invasive diagnostic tests. This approach has
been tested for further reﬁning absolute CVD risk assessment
beyond CAC in speciﬁc subgroups [11], and has recently beenr the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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a follow-up scan in subjects with an initial CAC ¼ 0.
In this issue of Atherosclerosis, Brodov et al. [12] provided an
excellent example of the multi-imaging approach. In a cohort of
1648 subjects with CAC¼ 0 from the EISNER Registry, thoracic aorta
calcium (TAC) scoring was assessed as a predictor of CAC conver-
sion (CAC > 0) after a mean follow-up of 5 years. Subjects with a
baseline TAC > 100 had a 37% conversion rate, compared to 22% in
the TAC ¼ 0 group. In multivariate analyses TAC > 100 was an in-
dependent predictor of CAC > 0. Of note, 77% of the study subjects
persisted to have CAC ¼ 0 after a mean follow-up of 5 years and
only 1% developed CAC>100, highlighting the durability of CAC¼ 0.
This is the ﬁrst study assessing the independent predictive value
of speciﬁc baseline TAC thresholds for CAC conversion, and pro-
vides new evidence supporting the notion of atherosclerosis as a
systemic process. Furthermore, among the possible combinations
of imaging tests, CAC þ TAC appears as one of the most attractive
strategies, as both can be assessed using the same CT imaging
acquisition protocol and software. Thus, TAC appears as a conve-
nient, non-further-irradiating, inexpensive “second” test, over-
coming some of the intrinsic limitations of a multi-modality
approach. Nevertheless, important limitations from the results re-
ported by Brodov et al. must be highlighted. Among the group who
converted to CAC > 0, just 4.5% had TAC > 100 at baseline, trans-
lating into a poor yield for changing clinical decision-making.
Moreover, among those with TAC > 100 at baseline, only 37%
developed CAC after 5 years of follow-up (i.e. 63% remained at
CAC ¼ 0). Furthermore, subjects with baseline TAC > 100 had a
mean BMI of 27 kg/m2, and at least 65% had other major CVD risk
factors. Thus, at least 65% of the subjects with baseline TAC > 100
probably would have beneﬁted from closer scrutiny according to
their clinical risk proﬁle alone.
Regardless of the “second” (or successive) test chosen, the use of
a multi-imaging strategy for predicting conversion to CAC > 0 raises
concerns regarding cost, radiation exposure, and potential down-
stream testing after incidental ﬁndings. From a clinical standpoint
the use of multiple tests should provide relevant information and
aid decision-making. Having two negative baseline tests should
reassure the clinician about the stability of that CAC ¼ 0 over time.
Yet, in the study by Brodov et al. the performance of TAC > 100 for
detecting CAC > 0 converters must be considered modest.
Furthermore, among participants with CAC ¼ 0 and TAC ¼ 0 at
baseline, 22% developed CAC during follow-up. What about these
patients?
2. Alternative approaches
The need and frequency of repeated testing over time is deter-
mined by both the natural history of the disease and the charac-
teristics of the test. CAC scoring is relatively inexpensive, is
associated with a low dose of radiation exposure and has a low rate
of false negatives. On the other hand, coronary atherosclerosis
development and progression [13] is directly affected by lifetime
exposure to traditional risk factors. This also holds for subjects with
CAC ¼ 0, which is commonly (but not always) the result of either a
low risk factor burden or a short life-long exposure at the time of
the scan. Accordingly in the study from Brodov et al., baseline
diabetes, hypertension and hypercholesterolemia were indepen-
dent predictors of CAC conversion, consistent with the results from
previous studies [14] and with the pathophysiology of atheroscle-
rosis. Of note, baseline diabetes was the strongest predictor of CAC
conversion at follow-up, even stronger than TAC > 100.
Thus, an alternative approach to the warranty period of CAC ¼ 0
reverts back to clinical features to identify those subjects more
likely to develop coronary atherosclerosis and calciﬁcations over agiven period of time. In this context, CAC and risk factor burden
provide complementary information, with CAC score deﬁning
baseline absolute risk and risk factors determining the “slope” of
the risk trajectory over time. This approach yields intuitive, easy-to-
follow and personalized follow-up algorithms built on information
already available to the treating clinician. Moreover, it allows
ﬂexibility, as it can adapt to changes in the patient's risk proﬁle over
time. Indeed, the concept of “warranty” implicitly assumes that the
patient will not engage in high-risk activities that would make a
negative result unstable. Thus, any warranty period or single-time
calcium conversion prediction could be compromised by the onset
of new risk factors. In such a context, an approach that de-
emphasizes a ﬁxed warranty period might help overcome the
limitations of single-time predictions and enable tailored ﬂexible
follow-up strategies.
3. Future directions
Advances in atherosclerosis-imaging technologies in the next
years will boost research in this area, expanding our knowledge
regarding safety, cost-effectiveness and the potential interplay
between imaging tests and predictions based on clinical features.
This will be particularly helpful in the electronicmedical record era,
in which clinicians will be able to leverage vascular disease infor-
mation from seemingly unrelated tests to improve risk assessment.
In such a context, studies like the one by Brodov et al. will improve
our understanding of the additional information provided by
different tests/measurements, aiding the selection of clinically
relevant information among a wealth of measurements. On the
other hand, future studies on the warranty period of negative fac-
tors such as CAC ¼ 0 will have to provide clear deﬁnitions of the
“outcome” (what deﬁnes the warranty? e any new CAC, only new-
onset increased burden of CAC, or an eventual CVD event?), as well
as the acceptable yield of repeat testing (number needed to scan in
order to detect a CAC conversion). These questions are nearly
completely unexplored.
Until further evidence is available, we should pay careful
attention to features that caution us about the need for a closer
follow-up in a given patient. Underscoring the role of the patient as
the main guarantor of a CAC ¼ 0, we should take advantage of the
excellent opportunity that CAC ¼ 0 offers to reinforce healthy
lifestyle recommendations, in order to extend that warranty period
asmuch as possible. Randomized trials have shown that reporting a
CAC ¼ 0 does not convey false reassurance or result in adverse
behavioral outcomes [15].
With the impending shift toward the primacy of imaging for
CVD risk assessment, we need further exploration of the concept of
the “warranty period” of atherosclerosis imaging results in order to
advance clinical decision-making.
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